Back to Search
Start Over
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
- Source :
- Oncology; 2024, Vol. 102 Issue 3, p239-251, 13p
- Publication Year :
- 2024
-
Abstract
- Introduction: Systemic therapy is recommended for patients with Child-Pugh A in hepatocellular carcinoma (HCC). We analyzed the outcomes of a cohort of patients with HCC who received either sorafenib (Sor), lenvatinib (Len) or atezolizumab plus bevacizumab (Atezo + Bev) as first-line systemic therapy for HCC, with the aim of identifying prognostic factors for survival. Methods: A total of 825 patients with advanced HCC and Child-Pugh A or B received either Sor, Len or Atezo + Bev as first-line systemic therapy. Liver function was assessed according to the Child-Pugh score and the modified albumin-bilirubin (mALBI) grade. Results: Prognosis was analyzed according to liver function such as Child-Pugh classifications, scores, and mALBI grades that worsened with a decline in liver function (p <0.001 for all). A Child-Pugh score of 7 was a factor significantly associated with OS. In patients with a Child-Pugh score of 7, an mALBI grade of 3 was an independent predictor of OS. In Child-Pugh B patients with HCC, receiving Atezo + Bev was identified as a factor associated with PFS. Conclusion: Determining the hepatic reserve of patients with unresectable HCC might be useful for identifying patents suitable for systemic treatment for HCC. Atezo + Bev might prolong the PFS of patients with a Child-Pugh score of 7. [ABSTRACT FROM AUTHOR]
- Subjects :
- LIVER physiology
THERAPEUTIC use of antineoplastic agents
COMBINATION drug therapy
PEARSON correlation (Statistics)
STATISTICAL significance
BEVACIZUMAB
FISHER exact test
LOGISTIC regression analysis
SORAFENIB
TREATMENT effectiveness
RETROSPECTIVE studies
MANN Whitney U Test
CHI-squared test
MULTIVARIATE analysis
DESCRIPTIVE statistics
IMMUNE checkpoint inhibitors
LONGITUDINAL method
KAPLAN-Meier estimator
LOG-rank test
LUNG tumors
STATISTICS
CANCER patient psychology
PROGRESSION-free survival
DATA analysis software
HEPATOCELLULAR carcinoma
LIVER function tests
OVERALL survival
PROPORTIONAL hazards models
Subjects
Details
- Language :
- English
- ISSN :
- 00302414
- Volume :
- 102
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 175912642
- Full Text :
- https://doi.org/10.1159/000533859